Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split effective January 25, 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease
Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
